Encompass Health (EHC)
(Delayed Data from NYSE)
$84.77 USD
+0.80 (0.95%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $84.75 -0.02 (-0.02%) 7:26 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Encompass Health (EHC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$97.11 | $108.00 | $94.00 | 15.65% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Encompass Health comes to $97.11. The forecasts range from a low of $94.00 to a high of $108.00. The average price target represents an increase of 15.65% from the last closing price of $83.97.
Analyst Price Targets (9 )
Broker Rating
Encompass Health currently has an average brokerage recommendation (ABR) of 1.10 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.10 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 90% and 10% of all recommendations. A month ago, Strong Buy made up 90%, while Buy represented 10%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/EHC.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 9 | 9 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.10 | 1.10 | 1.10 | 1.10 | 1.10 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/22/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/1/2024 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
4/25/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
3/6/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
2/9/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
2/8/2024 | Raymond James | John W Ransom | Strong Buy | Strong Buy |
2/7/2024 | William Blair | Jared Haase | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.10 |
ABR (Last week) | 1.10 |
# of Recs in ABR | 10 |
Average Target Price | $97.11 |
LT Growth Rate | 15.60% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 54 of 252 |
Current Quarter EPS Est: | 1.01 |